Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.
about
Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse.Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.Behavioral characterization of mouse models of neuroferritinopathy.Iron Toxicity in the Retina Requires Alu RNA and the NLRP3 InflammasomeT2-Imaging Changes in the Nigrosome-1 Relate to Clinical Measures of Parkinson's Disease.Significant glial alterations in response to iron loading in a novel organotypic hippocampal slice culture model.Iron Deposition Leads to Neuronal α-Synuclein Pathology by Inducing Autophagy Dysfunction.Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach.Biometals and their therapeutic implications in Alzheimer's disease.Lithium suppression of tau induces brain iron accumulation and neurodegeneration.Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration.Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease.Impact of high iron intake on cognition and neurodegeneration in humans and in animal models: a systematic review.Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies.Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Iron oxide nanoparticles may damage to the neural tissue through iron accumulation, oxidative stress, and protein aggregation.Iron overload causes endolysosomal deficits modulated by NAADP-regulated 2-pore channels and RAB7A.Iron Accumulation Is Not Homogenous among Patients with Parkinson's Disease.Mitochondrial Ferritin Protects Hydrogen Peroxide-Induced Neuronal Cell Damage.Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma.Metal concentrations and distributions in the human olfactory bulb in Parkinson's disease.Cerebellar Mild Iron Accumulation in a Subset of FMR1 Premutation Carriers with FXTAS.Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein.Iron-induced generation of mitochondrial ROS depends on AMPK activity.Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease.Two mTOR inhibitors, rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS.Iron modulates the activity of monoamine oxidase B in SH-SY5Y cells.The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.Biomarkers for Parkinson's Disease: Recent Advancement.The Aging of Iron Man.Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease.Ceruloplasmin in Parkinson's disease and the nonmotor symptoms.
P2860
Q27321138-2D0A50BD-6084-4FC2-A867-181C355B6066Q33776138-019EFC70-5B12-4B32-8063-300F0B808976Q35090866-38879DC0-518F-4DB1-8370-16396104C11EQ35782822-20B88E2E-0DE3-409E-BA66-66413F458D93Q37351959-7873C02E-0D11-4697-BAB2-E83F4DCA7EA1Q37390184-FC18CD20-4278-4EA9-B41A-C7DB2D771D1AQ37587232-2D332AAD-0369-44BB-9B47-B0710661C4DDQ37592662-20F3C84F-F76A-4FF6-A56C-A6BABFD27C22Q38263669-876EF72E-0980-4BB3-9F07-5D364B001B85Q38412707-FE927795-B2E4-4960-B289-808530A8AFE5Q38570991-01AE0B5E-7FAE-487C-8D1A-53BEF905893CQ38762283-5C63B626-593F-44E3-814F-9BA5547CEA0DQ38785723-7DC32DDE-6C7A-48CC-A663-5DB1B7797600Q38915163-A18B56E5-2F35-443E-A326-59773945FB0AQ38921067-1AC6112F-054F-4BC4-A646-705651FC4FE2Q39179797-0C56743C-9069-40D0-B424-437DE797C1E6Q39398994-0E8B5E04-30B3-43B7-9A16-D81A3B8F1BF9Q39627828-29FA7F87-FF1B-4E5C-B87F-1138B0531B39Q39763404-0D369EDD-3288-4992-884E-500CDD441AD1Q41108761-B58CD915-B706-4482-B25E-763F31CC0BE3Q41147841-E12E232D-A402-4B5D-AFD9-704218270BFDQ41621240-1C46FE9F-F4D5-4B77-9DF7-E0D904809E8EQ41637174-901EF24E-CFBE-4686-9553-27F09698ED53Q46349223-1BFB5732-12BB-4114-82E4-513F7E4B576EQ46352031-86132B0E-0FC2-4F09-A493-0BDF8B0C2469Q47914237-3E3367B9-DF3B-4B3D-9D56-989DE6B93D77Q48050909-80D8BDD2-9A19-4E2A-BDA2-2971C50CE8CFQ48058273-FA64B90C-F7F9-4435-AFF4-17464EEA66D5Q48432793-C3536039-936B-4B4D-9E56-BBED401E5C1CQ49942492-22B48EF4-4460-4D1E-9C84-71B674B7068EQ51758684-08D08C9F-252C-43F0-B5AD-9D3910876D3FQ52609727-1D57C08D-B7AF-4D82-B1C0-0454A0692799Q55237580-01086168-6F2D-4DA4-A9EF-34808FFDBBE8
P2860
Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Nigral iron elevation is an in ...... nt cause of neurodegeneration.
@en
type
label
Nigral iron elevation is an in ...... nt cause of neurodegeneration.
@en
prefLabel
Nigral iron elevation is an in ...... nt cause of neurodegeneration.
@en
P2860
P921
P356
P1476
Nigral iron elevation is an in ...... nt cause of neurodegeneration.
@en
P2860
P304
P356
10.1155/2014/581256
P407
P5008
P577
2014-01-16T00:00:00Z